Advanced hepatocellular carcinoma research hub

A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

This study is looking at a new way to treat advanced liver cancer. It combines two existing medicines, ipilimumab and nivolumab, given in a special way to see if it's safe and works well. This early-stage trial aims to find the best dose.

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)